Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6696-6701

  Querzoli, Patrizia ^a   Pedriali, Massimo ^a   Rinaldi, Rosa ^a   Lombardi, Anna Rita ^a   Biganzoli, Elia ^b   Boracchi, Patrizia ^b   Ferretti, Stefano ^a   Frasson, Claudia ^a   Zanella, Caterina ^a   Ghisellini, Sara ^a   Ambrogi, Federico ^b   Antolini, Laura ^b   Piantelli, Mauro ^c   Iacobelli, Stefano ^c   Marubini, Ettore ^b   Alberti, Saverio ^c   Nenci, Italo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN ANTIBODY; HORMONE ANTIBODY;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER RISK; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MICROMETASTASIS; NANOMETASTASIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE;

EID: 33845347364     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0569     Document Type: Article

References (35)

1. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
2. De Vita VT, Hellman S, Rosenberg SA. Cancer - principles and practice of oncology. 6th ed. Philadelphia: Lippincott J. B. Co.; 2001.
3. Olivotto IA, Truong PT, Speers CH. Staging reclassification affects breast cancer survival. J Clin Oncol 2003;21:4467-8.
4. Group ILBCS. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
5. Lara JF, Young SM, Velilla RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003;98:2105-13.
6. Nasser IA, Lee AK, Bosari S, et al. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 1993;24:950-7.
7. Cummings MC, Walsh MD, Hohn BG, et al. Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis. Am J Surg Pathol 2002;26:1286-95.
8. Clare SE, Sener SF, Wilkens W, et al. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997;4:447-51.
9. Cote RJ, Peterson HF, Chaiwun B, et al.; International Breast Cancer Study Group. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 1999;354:896-900.
10. Trojani M, de Mascarel I, Bonichon F, et al. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-6.
11. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993;80:459-63.
12. de Mascarel I, Bonichon F, Coindre JM, et al. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992;66:523-7.
13. McGuckin MA, Cummings MC, Walsh MD, et al. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996;73:88-95.
14. Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:2496-501.
15. Bianchi S, Sapino A, Bussolati G. [Guidelines concerning breast pathology in the course of mammographic screening programs. Working group on "Breast pathology in mammographic screening programs" of the European Communities]. Pathologica 1997;89:234-55.
16. Cserni G. A model for determining the optimum histology of sentinel lymph nodes in breast cancer. J Clin Pathol 2004;57:467-71.
17. Cserni G. Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of two different step sectioning and immunohistochemistry protocols in 246 patients. J Clin Pathol 2002;55:926-31.
18. Farshid G, Pradhan M, Kollias J, et al. Computer simulations of lymph node metastasis for optimizing the pathologic examination of sentinel lymph nodes in patients with breast carcinoma. Cancer 2000;89:2527-37.
19. Herndon JE, III, Harrell FE, Jr. The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. Stat Med 1995;14:2119-29.
20. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. Chichester: John Wiley and Sons; 1995.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1989;16:1141-54.
22. Fine JP, Gray R. A proportional hazard model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509
23. Vineis P, Duca PG, Pasqualini P. Manuale di metodologia epidemiologica. Rome: La Nuova Italia Scientifica; 1988.
24. Sedmak DD, Meineke TA, Knechtges DS, et al. Prognostic significance of cytokeratin-positive breast cancer metastases. Mod Pathol 1989;2:516-20.
25. Weaver DL, Krag DN, Ashikaga T, et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000;88:1099-107.
26. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7.
27. Steinhoff MM. Axillary node micrometastases: detection and biologic significance. Breast J 1999;5:325-9.
28. Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 2005;103:492-500.
29. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
30. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
31. Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants - or both? Cell 2003;113:821-3.
32. Gray JW. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 2003;4:4-6.
33. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
34. Colleoni M, Rotmensz N, Peruzzotti G, et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 2005;23:1379-89.
35. Dabbs DJ, Fung M, Landsittel D, et al. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J 2004;10:101-5.